143 related articles for article (PubMed ID: 35345371)
1. High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.
El Nahass YH; Nader HA; Sabet S; Nooh HA; Bassiony H; Kamel M; Samra MA; Mahmoud HK; El Metnawy WH; El Refaey FA
Asian Pac J Cancer Prev; 2022 Mar; 23(3):977-984. PubMed ID: 35345371
[TBL] [Abstract][Full Text] [Related]
2. IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics.
ElNahass YH; Badawy RH; ElRefaey FA; Nooh HA; Ibrahiem D; Nader HA; Mahmoud HK; ElMetnawy WH
Asian Pac J Cancer Prev; 2020 Mar; 21(3):721-725. PubMed ID: 32212799
[TBL] [Abstract][Full Text] [Related]
3. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations.
Zhou L; An J; Hou C; Ding Z; Qiu H; Tang X; Sun A; Chen S; Xu Y; Liu T; Wu D
Hematology; 2021 Dec; 26(1):340-347. PubMed ID: 33840380
[No Abstract] [Full Text] [Related]
5. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes.
Devillier R; Mansat-De Mas V; Gelsi-Boyer V; Demur C; Murati A; Corre J; Prebet T; Bertoli S; Brecqueville M; Arnoulet C; Recher C; Vey N; Mozziconacci MJ; Delabesse E; Birnbaum D
Oncotarget; 2015 Apr; 6(10):8388-96. PubMed ID: 25860933
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF; Elshorbagy S; Mohamed H; Embaby A; Khamis T; Sameh R; Sabbah NA; Hussein S
Cancer Biomark; 2021; 32(3):379-389. PubMed ID: 34487021
[TBL] [Abstract][Full Text] [Related]
7. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation].
Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN
Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
[No Abstract] [Full Text] [Related]
10. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
11. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
12. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
Zhang A; Wang S; Ren Q; Wang Y; Jiang Z
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations.
Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ
Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592
[TBL] [Abstract][Full Text] [Related]
14. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
15. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.
Zarnegar-Lumley S; Alonzo TA; Gerbing RB; Othus M; Sun Z; Ries RE; Wang J; Leonti A; Kutny MA; Ostronoff F; Radich JP; Appelbaum FR; Pogosova-Agadjanyan EL; O'Dwyer K; Tallman MS; Litzow M; Atallah E; Cooper TM; Aplenc RA; Abdel-Wahab O; Gamis AS; Luger S; Erba H; Levine R; Kolb EA; Stirewalt DL; Meshinchi S; Tarlock K
Blood Adv; 2023 Oct; 7(19):5941-5953. PubMed ID: 37267439
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
Lipilkin PV; Kulaeva ED; Mashkina EV
Leuk Res; 2022 Sep; 120():106910. PubMed ID: 35785697
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and prognosis analysis of patients with de novo ASXL1-mutated AML treated with the C-HUNAN-AML-15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group.
Zeng M; Chen K; Tian X; Zou R; Feng X; Li C; Li J; Zheng M; Mai H; Yang L; He Y; Xu H; Wen H; He X
Cancer Med; 2023 Jun; 12(12):13182-13192. PubMed ID: 37132266
[TBL] [Abstract][Full Text] [Related]
18. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
[TBL] [Abstract][Full Text] [Related]
19. ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.
El-Sharkawi D; Ali A; Evans CM; Hills RK; Burnett AK; Linch DC; Gale RE
Leuk Lymphoma; 2014 Jun; 55(6):1326-31. PubMed ID: 23952244
[TBL] [Abstract][Full Text] [Related]
20. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
